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Background: The frequency of over-expression of human epidermal growth factor receptor-2 (HER-2) in
bladder cancer is one of the highest among all human malignancies. This over-expression is thought to play a
role in aberrant proliferation of cancer cells. Studies on HER-2 expression in bladder carcinoma have shown
heterogeneous results.
Purpose: The aim of the study was to evaluate the status of HER-2 protein expression in patients with
invasive carcinomas of the urinary bladder as related to tumor grade and stage.
Materials and methods: Archival samples from 39 patients (6 women, 33 males) with urinary bladder cancer
were analyzed for HER-2 over-expression, using immunohistochemistry with the HercepTest.
Results: HER-2 over-expression was observed in 23/39 tumors (59%) and was more frequent in high-grade
than in low-grade carcinomas, but the difference was not statistically significant. A significant correlation was
established between HER-2 over-expression and tumor stage (p0.011). HER-2 expression was more
frequent in transitional cell carcinomas (TCC) and adenocarcinomas (AC) as compared with squamous cell
carcinoma (SCC). Patients’ age and sex were not related to HER-2 over-expression.
Conclusion: Over-expression of HER-2 was frequent in carcinomas of the urinary bladder. Knowing the
HER-2 status would be helpful in formulating a rational treatment strategy for patients with urinary bladder
cancer.
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B
ladder cancer is a common malignancy in the
genitourinary tract, and transitional cell cancer
(TCC) accounts for  90% of all bladder cancers.
It is a prevalent disease and ranks ninth in the global
cancer incidence, with 356,000 annual new cases and
145,000 annual deaths (1, 2). Bladder cancers are
classified as superficial (80%) and invasive disease
(20%) on the basis of their histological appearance.
Transurethral resection (TUR) with or without intra-
vesical treatment is the therapy-of-choice in superficial
bladder cancers, while radical cystectomy is needed in
invasive disease (3, 4). However, 5-year survival rates
following radical treatment for tumors of all stages
remain low, around 4050%, due to a high risk of
recurrence or occult metastasis (5, 6).
Despite the fact that the most common prognostic
markers are conventional clinico-pathologic parameters,
such as tumor stage and grade, which are subject to
considerable intra- and inter-observer variation, it is
difficult to predict accurate prognosis with any single
factor. However, accurate estimation of the biological
behavior of these tumors is important to select the
appropriate treatment. Therefore, more reliable prognos-
tic factors are urgently needed, the prime interest being
currently focused on protein and genetic markers (79).
Human epidermal growth factor receptor-2 (HER-2) is
a trans-membrane tyrosine kinase receptor of the epider-
mal growth factor (EGF) receptor family. HER-2 plays a
fundamental role in cell growth, survival, and migration,
and abnormal activation of HER-2 has been proposed to
lead to oncogenic transformation. The role of HER-2 has
been most thoroughly studied in breast cancer, where
constitutivelyactiveHER-2isover-expressedin1822%of
casesandshowntocorrelatewithapoorprognosis(10,11).
It has been shown that this protein is involved in
pathogenesis of urinary bladder carcinomas as well, to an
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However, the prognostic value of this protein in bladder
cancer has not been well established, and also the true
prevalence of HER-2 expression in this disease remains
uncertain. A possible involvement of HER-2 receptor in
the proliferation of invasive urothelial carcinomas has
prompted trials with HER-2 targeted therapies in locally
advanced or metastatic disease (14).
In this retrospective study, we used immunohistochem-
istry (IHC) to evaluate the HER-2 protein expression in
bladder carcinomas in relation to tumor histology, grade
and stage.
Material and methods
Clinical samples
Archival samples of 39 invasive urinary bladder carcino-
mas was examined in the present study: All the tumor
samples were collected from the Pathology Department,
Faculty of Medicine, Garyounis University, Benghazi,
Libya, derived from years 2006 to 2010. Only invasive
bladder tumors were included based on availability of
representative paraffin blocks. Of these 39 cases, 33
patients were male and 6 were women, with the mean
age of 64.5 years (range: 4780 years). Histological
diagnosis and tumor grading were performed by an
experienced pathologist, following the World Health
Organization (WHO) classification. Clinical staging was
made according to the American Joint Committee on
Cancer system in a blinded fashion. Key features of the
patients and their tumors are shown in Table 1.
Immunohistochemical (IHC) method for HER-2
Paraffin-embedded tumor specimens were cut at 5 mm
and subjected to IHC staining with the Food and Drug
Administration (FDA)-approved HercepTest
†
(Ventana
Medical System, Inc., Tucson, AZ, USA). The IHC
analysis was done using an automated system (Bench-
Mark XT, Ventana Medical System, Tucson, AZ, USA).
In brief, tissue sections were incubated with the primary
HER-2 antibody (Confirm
TM, Anti HER-2 primary anti-
body/4BS), followed by the secondary antibody, perox-
idase-anti-peroxidase complex (PAP), and final detection
of immunoreactivity by the diaminobenzidine (DAB)
substrate. After staining, the sections were dehydrated
in ethanol, cleared in xylene, and covered with Mountex
and cover slips.
Scoring of HER-2 over-expression
Stained sections were reviewed independently by two
pathologists, both blinded to the clinical outcome.
Scoring was done using the following system: 1,a t
most faint, equivocal, and incomplete membranous
staining; 2, unequivocal, complete membranous pat-
tern, with moderate intensity; and 3, complete and
strong membranous pattern. Tumors with a score of 2 or
3 were considered as HER-2 positive (15). The staining
index (I) was calculated using the following formula:
I0  f0  1  f1  2  f2  3  f3
Where f0, f1 and f3 represent the fraction of the cells
showing a defined level of staining intensity (from 0 to 3).
Theoretically, the index ranges from 0 to 3 (16, 17).
Statistical analysis
SPSS for Windows SPSS 19.0.1 (IBM, NY, USA) was
used for statistical analysis. Frequency tables were ana-
lyzed using the Chi-square test, with Fisher’s exact test
(where appropriate), or likelihood ratio (LR) statistics to
assess the significance between categorical variables.
Differences in the means of continuous variables were
analyzed using ANOVA (analysis of variance) or non-
parametric tests (Mann-Whitney, Kruskal-Wallis) tests.
Reported p-values are from two-sided tests, and in all
analysis pB0.05 was regarded as statistically significant.
Results
In interpreting HER-2 immunostaining, HER-2 positivity
was indicated by membranous golden-brown staining.
The cases with only cytoplasmic staining were considered
negative, irrespective of the staining intensity. Of the 39
bladder carcinomas, 16 (41%) were considered negative
(staining intensity 0 or 1 in 4 and 12 patients,
respectively) (Fig. 1 A, B), whereas 23 (59%) were
considered positive (staining intensity 2 or 3 in 10
Table 1. Key features of the patients and their tumors
Variable Number Percentage%
Patients
Male 33 84.6
Female 6 15.4
Age (years)
Range 4780 
Mean 64.51 
Median 67.00 
Histological type
TCC 36 92.3
AC 1 2.6
SCC 2 5.1
Grade
Low grade 27 69.2
High grade 12 30.8
Stage
Stage 1 29 74.4
Stage 2 9 23.1
Stage 3 1 2.5
TCC, transitional cell carcinoma; AC, adenocarcinoma; SCC,
squamous cell carcinoma.
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expression was invariably negative in the normal urothe-
lium adjacent to the tumor (Fig. 2).
The present study revealed a significant correlation
between HER-2 expression and the tumor stage (p
0.011). Although there was no statistically significant
association (p0.21) between HER-2 and tumor grade,
HER-2 showed over-expression more often in high-grade
(8/12, 66.6%) than in low-grade tumors (12/27 44.4%).
HER-2 did not show any correlation with age or sex.
However, HER-2 expression was higher in TCC and
adenocarcinomas (AC) as compared to squamous cell
carcinoma (SCC) (p0.029) despite the small number of
AC and SCC samples used. The associations of HER-2
expression with clinical and pathological variables are
shown in Table 2.
Discussion
The first report of increased amplification and expression
of the HER-2 in bladder carcinoma (18) enthused interest
in the role of this oncogene in tumor progression.
Prevalence of HER-2 expression in urothelial carcinomas
has ranged from 2% to 81% (1934). Moreover, its
prognostic significance is highly controversial, with
several conflicting results in the literature. Thus, although
some studies (24, 26) have found correlation between
HER-2 amplification/over-expression and more aggres-
sive clinical behavior, others (19, 21, 25) have found no
such prognostic significance, and still some others (20, 22,
23, 27) have linked HER-2 with a more favorable clinical
outcome. Differences in the frequency of HER-2 expres-
sion and its prognostic significance in urothelial cancer
are most likely explained by the use of different techni-
ques, including assessment of the HER-2 status (i.e. gene
amplification or protein over-expression), detection
methods (i.e. PCR, fluorescence in situ hybridization,
and IHC), as well as definition of HER-2 positivity. Thus,
the available literature in this field is extremely difficult to
compare, and definite conclusions are hard to draw from
the accumulated data.
Inthepresentseries,therewasapositiveHER-2statusin
23 (59%) cases of bladder cancer. This rate is within the
range of previously published data. Previous studies on
HER-2 expression in bladder carcinoma using Western
AB
CD
Fig. 1. HER-2 immunostaining of invasive urothelial carcinoma cells showing: (A) IHC 0 score (100), (B) IHC 1 score
(200), (C) IHC 2 score (200) and (D) IHC 3 score (200).
Over-expression of HER-2
Citation: Libyan J Med 2012, 7: 14694 - DOI: 10.3402/ljm.v7i0.14694 3
(page number not for citation purpose)blot analysis and IHC have found a correlation between
increased HER-2 expression and both higher tumor stage
and grade (3539). Our study confirmed these findings.
We assessed HER-2 expression by IHC, which is the
method most commonly used also for HER-2 status
determination in breast cancer, andwe found a significant
correlation between HER-2 over-expression and tumor
stage (p0.011), and a trend (albeit not significant) for
higher HER-2 expression with high-grade tumors. Others
(19,27,40)havereportedasignificantassociationbetween
HER-2 over-expression and a higher tumor grade, but
not with the tumor stage. Thus, Kru ¨ger et al. (41) studied
HER-2 expression in patients undergoing radical cystect-
omy for muscle-invasive carcinoma using the Hercep
Test. HER-2 over-expression was associated with high-
grade bladder cancers but showed no correlation with the
tumorstage.Similarly,inarecentstudy(42)on59patients,
HER-2 over-expression was significantly correlated with
the differentiation grade but not with the tumor stage.
In two other studies (43, 44) there was no significant
association between HER-2 and either pathological
staging or tumor grading. Similarly, in a series of 53
bladder cancers, no significant correlation was found
between HER-2 and stage or grade (45). Furthermore, in
that study, the authors reported no significant difference
between TCC and SCC groups, which is in contrast to
our current study, where HER-2 expression was signifi-
cantly more frequent in TCC and AC than in SCC
(p0.029), notwithstanding the small number of AC and
SCC samples in the current study.
It seems likely that the reported variations in HER-2
expressioninurothelialcancermaybetheresultnotonlyof
true biological variations but also of several confounding
variablesinthesestudies.Theseincludetheuseofdifferent
Fig. 2. Normal urothelium showing negative HER-2
immunostaining (400).
Table 2. The associations of HER-2 expression with clinical and pathological variables
HER-2 expression status N (%)
Variable N (%) 0 1 2 3 P
Total 39 (100) 4 (10.2) 12 (30.8) 10 (25.7) 13 (33.3) 
Gender
Female 6 (15.4) 1 (16.7) 0 (0) 2 (33.3) 3 (50) 0.17
Male 33 (84.6) 3 (9.1) 12 (36.3) 8 (24.2) 10 (30.4)
Stage
I 29 (74.4) 3 (10.3) 11 (38) 9 (31) 6 (20.7) 0.011
II 9 (23.1) 1 (11.1) 1 (11.1) 1 (11.1) 6 (66.7)
III 1 (2.5) 0 (0) 0 (0) 0 (0) 1 (100)
Grade
Low grade 27 (69.2) 4 (14.8) 11 (40.7) 7 (26) 5 (18.5) 0.21
High grade 12 (30.8) 2 (16.6) 2 (16.6) 2 (16.6) 6 (50)
Histological type
TCC 36 (92.3) 4 (11.1) 13 (36.1) 9 (25) 10 (27.8) 0.029
AC 1 (2.6) 0 (0) 0 (0) 0 (0) 1 (100)
SCC 2 (5.1) 2 (100) 0 (0) 0 (0) 0 (0)
TCC, transitional cell carcinoma; AC, adenocarcinoma; SCC, squamous cell carcinoma.
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(i.e. cytoplasmic or membrane staining), and different
scoring criteria.
Despite the inconclusive data on the prognostic value
of HER-2 as an independent marker of tumor progres-
sion, there may be a therapeutic role for an anti HER-2
agent such as trastuzumab in cancer treatment. Available
data clearly demonstrate that the development of new
drugs will have little, if any, chance of success if it is not
guided by in-depth knowledge of disease biology. How-
ever, using biologic agents to target key molecular path-
ways, such as those regulated by HER family members,
may be effective. Indeed, the positive results achieved by
trastuzumab in breast and gastric HER-2 positive tumors
support this approach (46). Combining trastuzumab with
chemotherapy in HER-2 positive advanced gastric cancer
was significantly more effective than chemotherapy alone
(47) and has a favorable toxicity profile (48). The efficacy
of trastuzumab in breast and gastric cancer patients has
led to investigation of its antitumor activity in patients
with HER-2 positive cancers, including urothelial carci-
nomas. Therefore, all patients with advanced or meta-
static bladder cancers should be tested for HER-2 status
for selection of proper candidates who may benefit from
adjuvant HER-2 targeted therapy.
Conclusion
The present study demonstrates a statistically significant
(p0.011) association between HER-2 over-expression
and increased tumor stage, as well as a statistically
insignificant (p0.21) increase in protein expression
in higher grade tumors. Assessment of HER-2 status
can be helpful in identifying patients at high-risk of
disease progression who may benefit from adjuvant
HER-2-targeted therapy after radical cystectomy. Future
prospective studies on HER-2 expression with chemo-
sensitivity and efficacy of HER-2-targeted therapies in
urothelial carcinomas are warranted.
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